Take­da’s post-merg­er deals con­tin­ue as OTC sub­sidiary is pre­pared for sale

Take­da has been bur­dened un­der moun­tains of debt since ac­quir­ing Shire for $62 bil­lion 18 months ago, but one of the com­pa­ny’s biggest moves …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.